Federal Register / Vol. 63, No. 126 /Wednesday, July 1, 1998 / Notices 35933

underwriting and dealing to a limited

extent in all types of equity securities,

other than ownership interest in openend investment companies; making,

acquiring and servicing loans and other

extensions of credit, pursuant to §

225.28(b)(1) of Regulation Y; providing

investment and financial advisory

services, pursuant to § 225.28(b)(6) of

Regulation Y; arranging commercial or

industrial real estate equity financing,

pursuant to § 225.28(b)(2)(ii) of

Regulation Y; underwriting and dealing

in obligations of the United States and

Canada, general obligations of U.S.

States, Canadian provinces, and their

political subdivisions, and other

obligation in which state member banks

may underwrite and deal under 12

U.S.C. 24 and 335, pursuant to §

225.28(b)(8) of Regulation Y; and

providing securities brokerage, private

placement, and riskless principal

services, pursuant to § 225.28(b)(7)(i),

(ii), and (iii) of Regulation Y. The

proposed activities are currently being

conducted, directly or indirectly, by the

subject entities with Board approval.

(See Bank of Boston Corp., 83 Fed. Res.

Bull. 42 (1997) and Bank America Corp.,

83 Fed. Res. Bull. 1008 (1997)).

Board of Governors of the Federal Reserve

System, June 25, 1998.

Robert deV. Frierson,

Associate Secretary of the Board.

[FR Doc. 98–17453 Filed 6–30–98; 8:45 am]

BILLING CODE 6210–01–F

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Office of the Secretary

Findings of Scientific Misconduct;

Terry D. Reisine, Ph.D.

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

SUMMARY: Notice is hereby given that

the Office of Research Integrity (ORI)

has made a final finding of scientific

misconduct in the following case:

Terry D. Reisine, Ph.D., University of

Pennsylvania: Based upon ‘‘The Dean’s

Proposed Findings of Fact’’ and

‘‘Memorandum on Issues Not Fully

Addressed in Findings of Fact,’’

forwarded to ORI by the University of

Pennsylvania, dated October 25, 1996

(Findings and Memorandum), and ORI’s

oversight review of the evidence

provided, ORI finds that Terry D.

Reisine, Ph.D., former Professor,

Department of Pharmacology,

University of Pennsylvania, engaged in

scientific misconduct in biomedical

research supported by Public Health

Service (PHS) grants.

Specifically, ORI finds that the

Respondent falsified results related to

the measurement of cyclic AMP in

cultured, transfected cells by falsely

representing in manuscripts and

publications the number of experiments

conducted, and by falsifying and/or

fabricating some of the substantive data

presented in those manuscripts and

publications. Moreover, ORI finds that

the Respondent attempted to falsify data

by directing members of his laboratory

to construct figures and tables with false

values in the preparation of

manuscripts.

Dr. Reisine has entered into a

Voluntary Exclusion Agreement with

ORI. The settlement is not an admission

of liability on the part of the

Respondent, and Dr. Reisine denies

having committed scientific

misconduct. Pursuant to the Agreement,

Dr. Reisine has agreed to the following:

(1) Respondent agreed to exclude

himself voluntarily for a period of three

(3) years beginning on June 11, 1998,

from any contracting or subcontracting

with any agency of the United States

Government, and from eligibility for or

involvement in nonprocurement

transactions (e.g., grants and cooperative

agreements) of the United States

Government as defined in 45 CFR part

76 (Debarment Regulations).

(2) Respondent agreed to exclude

himself voluntarily from serving in any

advisory capacity to PHS including, but

not limited to, service on any PHS

advisory committee, board, and/or peer

review committee, or as a consultant for

a period of three (3) years, beginning on

June 11, 1998.

(3) Within 30 days of the effective

date of the Agreement, Respondent

agreed to submit letters to the following

journals requesting correction of the

corresponding articles. The corrections

are warranted by the following findings

of the Findings and Memorandum:

a. The Journal of Biological Chemistry

Kong, H., Raynor, K., Yasuda, K., Moe, S.T.,

Portoghese, P.S., Bell, G.I., and Reisine,

T. ‘‘A single residue, aspartic acid 95, in

the gamma opioid receptor specifies

selective high affinity agonist binding.’’

J. Biol. Chem. 268:23055–23058, 1993.

i. The results in Table 1 are stated in the

table legend to be based on four (4)

experiments with calculated SEM values and

Hill coefficients when, in fact, the majority

of the listed compounds were tested only

once, and a few tested only twice.

ii. Figure 2 data are stated in the figure

legend to be the means of three (3) different

experiments when, in fact, most of the results

were based on a single experiment.

b. The Journal of Pharmacology and

Experimental Therapeutics

Raynor, K., Kong, H., Hines, J., Kong, G.,

Benevoc, J., Yasuda, K., Bell, G.I., and

Reisine, T. ‘‘Molecular mechanisms of

agonist-induced desensitization of the

cloned mouse kappa opioid receptor.’’ J.

Pharmacol. Exp. Ther. 270:1381–1386,

1994.

i. The figure legend for Figures 3A, 3C, and

3D claimed that the values shown were the

average of three (3) different experiments

when, in fact, the results were from only one

(1) experiment.

ii. The figure legend for Figure 4B claimed

that the values shown were the average of

four (4) different experiments when, in fact,

the results were from only three (3)

experiments.

iii. Figures 3A, 3C, and 3D each show

several levels of adenyl cyclase inhibition

that do not reflect the actual results obtained

in duplicate cyclic AMP assays.

c. Molecular Pharmacology

Reisine, T., Kong, H., Raynor, K., Yano, H.,

Takeda, J., Yasuda, K., and Bell, G.I.

‘‘Splice variant of the somatostatin

receptor 2 subtype, somatostatin receptor

2B, couples to adenylyl cyclase.’’ Mol.

Pharmacol. 44:1016–1020, 1994.

i. The legend for Figure 3A claims that

three (3) experiments were performed when,

in fact, only two (2) experiments were

performed for the SSTR2B mutants.

ii. The legend for Figure 3B claims that the

values presented are the average of two (2)

different experiments when, in fact, the

inhibition curve shown was based on a single

experiment.

FOR FURTHER INFORMATION CONTACT:

Acting Director, Division of Research

Investigations, Office of Research

Integrity, 5515 Security Lane, Suite 700,

Rockville, MD 20852, (301) 443–5330.

Dorothy K. Macfarlane,

Acting Director, Office of Research Integrity.

[FR Doc. 98–17411 Filed 6–30–98; 8:45 am]

BILLING CODE 4160–17–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Agency for Toxic Substances and

Disease Registry

[Program Announcement 98095]

Enhancement of Local Public Health

Departments Participation in

Brownfields Decisions and Actions;

Notice of Availability of Funds

Introduction

The Agency for Toxic Substances and

Disease Registry (ATSDR) announces

the availability of fiscal year (FY) 1998

funds for a cooperative agreement

program for a pilot activity with a select

number of local health departments to

demonstrate effective public health